TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Zhaoke Ophthalmology Ltd. ( (HK:6622) ).
Zhaoke Ophthalmology Limited announced that the FDA has cleared its IND application for the CsA Ophthalmic Gel, a core product for treating moderate-to-severe dry eye disease. The gel, which has shown promising results in previous trials, is expected to improve patient compliance due to its once-daily application and rapid onset of action, potentially enhancing the company’s position in the ophthalmic treatment market.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited is a company incorporated in the British Virgin Islands and continued in the Cayman Islands, focusing on the development of ophthalmic products. It specializes in innovative treatments for eye diseases, with a market focus on products like the CsA Ophthalmic Gel for moderate-to-severe dry eye disease.
Average Trading Volume: 2,903,799
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.57B
For an in-depth examination of 6622 stock, go to TipRanks’ Stock Analysis page.